Another possible option that would allow the identification of CMMRD in brain tumors would be sequencing to determine MSI, mutation burden and signatures, and other alterations characteristic of these tumors, such as POLE or POLD1 variants. This evidence concerns the gene POLD1 and brain neoplasm.